Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Amodiaquine Hydrochloride

FDA-approved product (tablet, oral), marketed as Camoquin Hydrochloride.

Registered studies
50+
Lab records
1
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Amodiaquine Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Malaria

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Aminoquinolines
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC P01BA06

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA49.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli37.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae18.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis14.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 0 of 1 lab record
Open Amodiaquine Hydrochloride in ChEMBL Registered studies below
Show the 1 laboratory record, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Amodiaquine Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania

    NCT00146731 · start 2004-01

    Registered record
    Registry ID
    NCT00146731
    Conditions
    Malaria
    Interventions
    SP; SP + amodiaquine; AQ + artesunate; chlorproguanil-dapsone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2004-01
    Completion
    2007-09
    Enrolment
    310

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionSP; SP + amodiaquine; AQ + artesunate; chlorproguanil-dapsone
    PhasePhase 3
    Registry statusCompleted

  • Trial of the Effectiveness of AQ/AS, SP/AQ and SP/CQ for Uncomplicated Malaria in Gambian Children

    NCT00118807 · start 2003-08

    Registered record
    Registry ID
    NCT00118807
    Conditions
    Malaria
    Interventions
    Amodiaquine plus artesunate (AQ/AS); Sulfadoxine-pyrimethamine plus chloroquine (SP/CQ); Sulfadoxine-pyrimethamine plus amodiaquine (SP/AQ)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-08
    Completion
    2004-02
    Enrolment
    1,800

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionAmodiaquine plus artesunate (AQ/AS); Sulfadoxine-pyrimethamine plus chloroquine (SP/CQ); Sulfadoxine-pyrimethamine plus amodiaquine (SP/AQ)
    PhasePhase 3
    Registry statusCompleted

  • Chloroquine and Amodiaquine for Treatment of Malaria in Children

    NCT00137514 · start 2001-03

    Registered record
    Registry ID
    NCT00137514
    Conditions
    Malaria, Falciparum
    Interventions
    chloroquine; amodiaquine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2001-03
    Completion
    2004-05
    Enrolment
    720

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum
    Interventionchloroquine; amodiaquine
    PhasePhase 4
    Registry statusCompleted

  • Efficacy, Effect on Gametocytes and Tolerability of the Addition of Artesunate to Amodiaquine in Colombia

    NCT00378625 · start 2000-04

    Registered record
    Registry ID
    NCT00378625
    Conditions
    Malaria,Falciparum; Malaria; Antimalarials
    Interventions
    Artesunate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2000-04
    Completion
    2006-03
    Enrolment
    360

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria,Falciparum; Malaria; Antimalarials
    InterventionArtesunate
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of Artesunate-amodiaquine (AS-AQ) in Children With Malaria and Severe Acute Malnutrition, Madaoua, Niger 2010

    NCT01204411

    Registered record
    Registry ID
    NCT01204411
    Conditions
    Malaria, Falciparum; Malnutrition; Child
    Interventions
    Artesunate-amodiaquine fixed-dose combination
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria, Falciparum; Malnutrition; Child
    InterventionArtesunate-amodiaquine fixed-dose combination
    PhasePhase 4
    Registry statusWithdrawn